Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T17:08:09.140Z.
Calculation as of: 2026-10-06T17:08:09.140Z.
Quote observation: 2026-10-06T17:04:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 16c1118283d3d380e79e54cd720e88a66b4293c4936e446a72c17353f5d031e1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
NeuroOne Medical Technologies Corporation
Market Cap
$9.57M
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| NeuroOne Medical Technologies Corporation (NMTC) | $9.57M | N/A |
| Ainos, Inc. (AIMD)vs › | $9.76M | N/A |
| SeaStar Medical Holding Corporation (ICU)vs › | $9.46M | N/A |
| MetaVia Inc. (MTVA)vs › | $9.88M | N/A |
| Jasper Therapeutics, Inc. (JSPR)vs › | $9.16M | N/A |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $9.14M | N/A |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.08M | N/A |
| Senti Biosciences, Inc. (SNTI)vs › | $10.33M | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.34M | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $10.44M | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
